The p53 pathway is nearly invariably altered in sporadic (ex novo) GBMs: loss of p53, through either point mutations that prevent DNA binding or loss of chromosome 17p, is a frequent and early event in the pathological progression of secondary GBM [15, 16]. Here, TP53 is linked to glioblastoma.